Using Genomic Analysis to Guide Individual Treatment in Glioblastoma
Completed
Conditions studied: Glioblastoma
In brief
The purpose of this study is to assess whether the use of genomics can help identify patient specific treatment choices in cancer. In order to test this, the investigators plan to use genomic sequencing technology to identify patient specific mutations in glioblastoma multiforme (GBM) as compared to normal cells to identify mutations. Further analysis will identify potential treatment targets and whether there are any drugs that could be used for these particular mutations. Follow up clinical data will be assessed to see if this individualized method of choosing treatment options can improve clinical outcomes in patients with GBM.
Key facts
- Study ID
- NCT02725684
- Run by
- Rockefeller University
- People needed
- 36
- Starts
- 2015-03-12
- Expected to finish
- 2017-07-07
- Last updated by the study team
- 2017-10-25
Who can join
Age: 3 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
You may qualify if…
- Histologically confirmed glioblastoma multiforme
- Enough tumor tissue available from initial surgery to obtain at least 5 ug DNA and 5 ug RNA
- Sufficient blood sample to obtain 5 ug DNA and 5 ug RNA
- Karnofsky score at least 60
- Life expectancy at least 6 months
You may not qualify if…
- Subjects not interested in further treatment of their brain tumor
Where it is running
- New York University Langone Medical Center — New York, New York, United States
- Memorial Sloan Kettering Cancer Center — New York, New York, United States
- Rockefeller University — New York, New York, United States
- Weill Cornell Medical College — New York, New York, United States
- Lenox Hill Hospital — New York, New York, United States
- North Shore University Hospital — New York, New York, United States
- Montefiore Medical Center — The Bronx, New York, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.